Millendo Therapeutics, Inc. Sustainability Profile
Millendo Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative therapies for endocrine diseases and cancers. Founded in 2015, Millendo has made significant strides in advancing its proprietary drug candidates, particularly in the areas of adrenal and pituitary disorders. The company’s flagship products, including its lead candidate, are designed to target specific hormonal pathways, offering unique treatment options that address unmet medical needs. With a commitment to scientific excellence, Millendo Therapeutics has positioned itself as a leader in the biopharmaceutical industry, achieving notable milestones in clinical development and regulatory advancements. As it continues to expand its operational footprint, Millendo remains dedicated to transforming the landscape of endocrine therapeutics.
DitchCarbon Score
How does Millendo Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Millendo Therapeutics, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Millendo Therapeutics, Inc.'s reported carbon emissions
In 2022, Millendo Therapeutics, Inc. reported total carbon emissions of approximately 48,398,000 kg CO2e, comprising 12,718,000 kg CO2e from Scope 1 and 36,208,000 kg CO2e from Scope 2 emissions. This reflects a decrease from 2021, where emissions were about 60,592,000 kg CO2e, with Scope 1 at 16,872,000 kg CO2e and Scope 2 at 43,967,000 kg CO2e. The trend indicates a commitment to reducing their carbon footprint, although specific reduction targets or initiatives have not been disclosed. Millendo's emissions data is cascaded from its corporate family, specifically from the merged entity that includes data from its parent organization. The company has not established any Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges, indicating a potential area for future commitment in climate action. Overall, while Millendo Therapeutics, Inc. has shown a reduction in emissions over the past year, the absence of formal reduction targets suggests that further strategic planning may be necessary to enhance their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Millendo Therapeutics, Inc.'s Industry?
How Carbon Intensive is Millendo Therapeutics, Inc.'s Location?
Millendo Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Millendo Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
